December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.820 -0.080 (-4.21%)
Streaming Delayed Price Updated: 10:59 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OS Therapies Incorporated Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
OS Therapies Provides U.S. Regulatory Update
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods... 
Via Newsfile
News headline image
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed... 
Via Newsfile
News headline image
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control ... 
Via Newsfile
Topics Death Intellectual Property
News headline image
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the... 
Via Newsfile
News headline image
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:... 
Via Newsfile
News headline image
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to... 
Via Newsfile
Topics Regulatory Compliance
News headline image
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS... 
Via Newsfile
News headline image
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S.,... 
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage... 
Via Newsfile
News headline image
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response... 
Via Newsfile
News headline image
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on... 
Via Newsfile
News headline image
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma... 
Via Newsfile
News headline image
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately... 
Via Newsfile
News headline image
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update
December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated... 
Via Newsfile
News headline image
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement... 
Via Newsfile
News headline image
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma
ATMP benefits include access to the Conditional Marketing Authorisation accelerated market access pathway in Europe, significantly reduced user fees for... 
Via Newsfile
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma ↗
Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S.,... 
Via Newsfile
News headline image
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or... 
Via Newsfile
News headline image
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's... 
Via Newsfile
News headline image
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway... 
Via Newsfile
News headline image
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or... 
Via Newsfile
News headline image
OS Therapies Enters into Warrant Inducement Agreements
$7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet... 
Via Newsfile
News headline image
OS Therapies Provides First Half 2026 Corporate Outlook
Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the... 
Via Newsfile
Topics Regulatory Compliance
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.